Member Info for Countach

C2645 says "A fool and his money are easily parted."

From the man that bought AML at 1910p + then bailed at a big loss.

🤣😂🤣😅🤣😂

You really are hilarious. Nobody can ever take you seriously.

C2645 repeating utter rubbish again.

Who are you going to take note of, C2645 the man who is down -94% on his investments and thinks the way to get wealthy is save in a piggy bank now

or Wall Street and 9 pro analysts?

AML - up 16% in a few weeks. Let the trend be your friend.

Given the new chair bought in large at 24p, you would think the board would support the SP.

I think the SP suffers from their lack of information. The output and timing of RNS updates is minimal at best.

I'd like to see much more meat on the reports.

Sales plans and actions, technical time frames.

More detail on expenditure and cost control.

It is a great product with amazing potential but the board does need a rocket up the backside.

On the flip side, the chair must be aware of something to put so much skin in himself, as well as the larger investors who put a lot extra in at 24p

AML SP up 16% in a few weeks.

C2645 down 94%

We don't think you should be advising anyone.

Taken from Wall Street

Aston Martin Lagonda Global Holdings

LSE:AML Stock Report

12 Feb, 2025

Data

Company Financials + 9 Analysts

AML Stock Overview

Engages in the design, development, manufacture, and marketing of luxury sports cars worldwide. More details

Snowflake Analysis

Good value with growth potential.

Rewards

Trading at 72.8% below our estimate of its fair value

Earnings are forecast to grow 60.38% per year

Risk Analysis

No risks detected for AML from our risk checks.

Fair Value

UK£

1.65

Current Price

UK£1.13

31.3% undervalued

intrinsic discount

C2645 says "A fool and his money are easily parted."

From the man that bought AML at 1910p + then bailed at a big loss.

🤣😂🤣😅🤣😂

You really are hilarious. Nobody can ever take you seriously.

Who are you going to take note of,

C2645 the AML board muppet

or Wall Street and 9 pro analysts?

Hearts2000 said "but not investing - these numbers look too risky"

That is fair enough, some people fear risk.

Not necessarily.

Aston easily out sold Ferrari in January yet they provided a positive trading statement creating an SP rise.

It is the world wide sales for Q4 with total value and margins + forward orders we are interested in.

March will be the main month of note for Aston in the UK.

Let's wait and see, not long now.

It has nothing to do with spoon feeding or ramping.

Yes, I agree the senior managers are way over paid.

I don't really like how the board is made up. The sales director is not listed as a board member which is quite astonishing given the nature of the business.

Yes, I would like to see full time board members who have years of experience selling into medical institutes.

However, those are not your stated risks which you have not provided factual information to support.

Happy to hear concerns supported by a rational data.

Your negativity for a share holder does not add up.

Peterrr,

Please link the device Olympus have that can perform the same procedure with accuracy that the Creo device does? Are you sure they have anything the same?

I see it like this.

Unfortunately cancer is hit to a huge number of the population. 1 in 2 people according to the ads on TV.

Yes, the Creo device won't help treat all types but the possibilities to help many millions of people is real.

Intuitive is a huge business value wise and could easily buy Creo core if they decide the device works well with their robotic machine.

The remaining 49% of Creo europe could well generate good sales now a bigger organisation is pushing it along.

They may take the income, or even sell the 49% and sell Creo core to Intuitive.

Or given a little more time sales will really ramp up.

Lots of potential situations which could start a hefty run on the SP

Peterrr,

You have a very negative view for a person holding shares?

Why did you buy and why have you not exited?

They said the same about the motor car and brick phone.

This has big potential hence why I am invested.

Peterrr,

You post the same negative view on other forums.

Afraid we will have to agree to disagree.

This is not some early stage pharma we are talking about.

The product works and nobody has disputed this.

It is a multi award winner.

The questions you should asking is,

Do I hold enough stock at this price to make good money when the SP runs?

Will I bail at 40p or hold nerves and wait for 60p ?

"Presently the can point to neither."

I disagree. There is no doubt about the product and the clinical / cost saving benefits.

They do need to focus hard now on selling.

It is only a matter of time before use of the products rockets or they get a buy out offer.

Good morning,

Please find the following research summary for Creo Medical Group plc (AIM: CREO), from Cavendish and Deutsche Numis.

Cavendish (reiterate 70p target price): "Creo Medical has announced it has received the relevant clearances in order to complete the 51% sale of Creo Europe (formerly Albyn Medical) to Micro-Tech, which was originally announced in September 2024. The sale is now completed in escrow, with net cash proceeds of c€30m expected to be received shortly, which will strengthen the group's balance sheet and support investment into the core business. The completion is in line with Creo's anticipated timeframe of 1Q25 and our current forecasts, which anticipated receipt of the cash at the start of the year. We remain positive on the shares and confident in Creo's technology and the benefits it can deliver to patients, care providers and investors."

Deutsche Numis (reiterate Buy recommendation and 45p target price): "In September 2024, Creo Medical announced a strategic partnership with Micro-Tech BV, a wholly owned subsidiary of China’s Micro-Tech and a binding agreement relating to the intended disposal of a 51% stake in Creo Europe (was Albyn Medical). The transaction valued Creo Europe at an equity value of €72m on a cash-free/debt-free basis, a >2x uplift from the €27m paid in 2020. Regulatory clearances have now been received and net proceeds of €30m are expected shortly."

Kind regards,

Phillip

Phillip Marriage

Senior Associate

D: +44 (0)20 7933 8780 |

75 King William St, London, EC4N 7BE | www.walbrookpr.com

Who are you going to take note of,

C2645 the board muppet

or Wall Street and 9 pro analysts?

Yes, if AML had no debt it would be lovely. However, the SP would be £40+ not 113p

The current SP is well below real value hence a likely runner.

Taken just from Wall Street

Aston Martin Lagonda Global Holdings

LSE:AML Stock Report

12 Feb, 2025

Data

Company Financials + 9 Analysts

AML Stock Overview

Engages in the design, development, manufacture, and marketing of luxury sports cars worldwide. More details

Snowflake Analysis

Good value with growth potential.

Rewards

Trading at 72.8% below our estimate of its fair value

Earnings are forecast to grow 60.38% per year

Risk Analysis

No risks detected for AML from our risk checks.

Fair Value

UK£

1.65

Current Price

UK£1.13

31.3% undervalued

intrinsic discount

C2645 says "A fool and his money are easily parted."

From the man that bought AML at 1910p + then bailed at a big loss.

🤣😂🤣😅🤣😂

You really are hilarious. Nobody can ever take you seriously.

The trading statement WILL be good and you will crawl back under a stone again just like you did after last one.

So many great new models, orders are racking up, margins will be up, average sale price will be up.

You will be wrong yet again.

I do not need a crystal ball to see this.